RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
Recursion Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.93B | $166.30M |
| Enterprise Value | $1.40B | $88.19M |
| PS Ratio | 35.23 | 3.65 |
| PB Ratio | 2.11 | 2.03 |
| P/TBV Ratio | 4.10 | 2.29 |
Enterprise value
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 25.54 | 2.51 |
Income (trailing twelve months)
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $54.86M | $58.34M |
| Gross Profit | $1.91M | $105.94M |
| Operating Income | -$544.01M | -$21.40M |
| Pretax Income | -$523.47M | -$14.34M |
| Net Income | -$518.88M | -$22.46M |
| EBITDA | -$465.65M | -$16.91M |
| EPS (Diluted) | -$1.04 | -$0.83 |
Margins
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 3.49% | 52.9% |
| Operating Margin | -991.7% | -44.0% |
| Pretax Margin | -954.3% | -13.3% |
| Profit Margin | -945.9% | -40.2% |
| EBITDA Margin | -848.9% | -30.2% |
| FCF Margin | -642.2% | -9.27% |
Returns
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -56.6% | -53.2% |
| Return on Assets (ROA) | -41.3% | -40.9% |
| Return on Invested Capital (ROIC) | -108.6% | -32.4% |
| Return on Capital Employed (ROCE) | -49.8% | -38.1% |
Growth
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -15.1% | 5.96% |
| Revenue Growth (3Y CAGR) | 23.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 79.9% | 6.48% |
Balance sheet
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $545.68M | $61.43M |
| Total Debt | $14.20M | $118.52M |
| Net Cash (Debt) | $531.49M | $15.35M |
| Net Cash Per Share | $0.99 | $0.66 |
| Equity (Book Value) | $915.00M | $49.09M |
| Book Value Per Share | $1.71 | $1.37 |
| Tangible Book Value | $471.77M | $23.52M |
| Working Capital | $483.58M | $76.81M |
Financial position
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 5.03 | 3.34 |
| Quick Ratio | 4.55 | 2.44 |
| Debt / Equity | 0.02 | 0.52 |
| Interest Coverage | -367.32 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$350.48M | -$12.35M |
| Capital Expenditures | -$1.79M | -$1.08M |
| Free Cash Flow | -$352.27M | -$20.22M |
| FCF Per Share | -$0.66 | -$0.42 |
Efficiency
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.39 |
| Revenue Per Employee | $1.10M | $404.87K |
| Profits Per Employee | -$10.38M | -$703.34K |
| Employee Count | 50 | 74 |
Dividends and yields
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -26.8% | -23.3% |
| FCF Yield | -18.2% | -8.72% |
| Buyback Yield | -20.1% | -0.59% |
| Shareholder Yield | -20.1% | 0.00% |
Shares
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 535,342,000 | 58,127,000 |
| Shares Change (YoY) | 41.1% | 10.9% |
| Shares Change (QoQ) | 0.66% | 0.54% |
| Float | 505,386,000 | 49,136,700 |
| Shares Held by Insiders | 5.60% | 11.6% |
| Shares Held by Institutions | 67.6% | 59.4% |
Taxes
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$4.58M | $79.87K |
Scores
| Measure | Recursion Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 0.26 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Recursion Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.